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BMN673 sensitizes rhabdomyosarcoma tumors to irradiation in vivo 
Connor Jacob 
Abstract 
 Bone and soft tissue sarcomas are mesenchymal tumors that occur rarely in adults, 
representing only 1% of total malignancies, but comprise up to 13% of malignant tumors in 
children.1 Rhabdomyosarcoma, a soft tissue sarcoma that commonly affects children, and 
osteosarcoma, a common bone sarcoma, exhibit aggressive tendency to metastasize and are 
associated with poor prognosis, high recurrence, and treatment failure.1 Sarcoma, as well as other 
forms of cancer, can be treated with chemotherapeutic drugs that inhibit the actions of the poly 
(ADP-ribose) polymerase enzyme family, which catalyze the transfer of ADP-ribose to proteins 
and contribute to the repair of single-stranded DNA breaks.2 Because some sarcoma cell lines 
display reduced DNA repair activity, these tumors might be relying on the PARP pathway for 
regular repair and maintenance of DNA during division.3 Because of this, PARP inhibition is 
targeted by molecules such as BMN673 (talazoparib), which has shown success as a treatment 
for BRCA1/2 and PTEN-deficient cell lines.2,4 BMN673, a recently developed PARP inhibitor 
with excellent in vitro activity, has been shown to increase tumor radiation sensitivity to a far 
greater extent than other PARP inhibitors; this action has been demonstrated to reduce tumor 
progression in vitro and shows promise as a treatment strategy in the clinic.2 Our study shows 
that the combination of BMN673 with radiation therapy reduces final rhabdomyosarcoma tumor 
size and slows tumor progression in mice. 
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Introduction 
 Sarcoma is relatively rare in the general population; however, sarcomas comprise 
approximately 13% of childhood tumors, and they commonly affect children less than five years 
old.1 Sarcomas, which are derived from primitive mesenchymal cells, are grouped into two 
classifications: bone and soft tissue.5 Sarcomas are heterogenous in clinical presentation and in 
molecular characterization because tumorigenesis might occur at different stages of 
mesenchymal differentiation.6 Primary bone sarcomas, other than parosteal osteosarcoma, 
disproportionately affect males. Osteosarcoma and Ewing sarcoma develop largely in individuals 
under fifteen years of age who are experiencing periods of rapid long bone growth.6 While bone 
sarcomas may occur at any location of any bone, they commonly present in areas with the 
greatest growth potential such as the metaphyseal region, in the case of osteosarcoma, or the 
diaphyseal region, in the case of Ewing’s sarcoma.7 Soft tissue sarcomas have a slight male 
predominance, and can develop in the joints, fat, nerves, dermis, blood vessels, and muscle; 
owing to this wide variety of potential origin, there are approximately 40 histologically different 
types of soft tissue sarcoma.5,8 The focus of our study is on rhabdomyosarcoma, a soft tissue cell 
line, and osteosarcoma, a bone cell line, two of the most common types of sarcoma. 
Clinicians frequently manage sarcoma with surgery and systemic chemotherapy; 
however, overall survival rates haven’t improved beyond 70% in recent decades despite research 
and advancements in diagnostic and therapeutic technology.1,6 Traditional chemotherapeutic 
agents commonly used to treat soft tissue sarcoma for the past several decades include 
doxorubicin (an anthracycline antibiotic that initiates dsDNA breaks by inhibiting 
topoisomerase), isfosfamide (an antineoplastic alkylator of DNA), gemcitabine (a deoxycytidine 
that inhibits DNA synthesis), and paclitaxel (an inhibitor of microtubule depolymerization during 
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mitosis).9 Newer pharmacotherapies include olaratumab (an IgG monoclonal antibody that 
targets a growth receptor), eribulin (a microtubule inhibitor), and various poly (ADP-ribose) 
polymerase inhibitors such as BMN673, or talazoparib, the molecule that we investigated in this 
study.2,9  
Inhibitors for poly (ADP-ribose) polymerase-1 (PARP1) and poly (ADP-ribose) 
polymerase-2 (PARP2), two important enzymes in the poly (ADP-ribose) polymerase (PARP) 
family, have been used with success in tumors that have deficiencies in the homologous 
recombination repair (HRR) pathway.2 Tumors with this deficiency include common cancers of 
the breast and the ovaries with deleterious BRCA or PTEN deficiencies, which lead to the 
reduced ability to repair double-stranded breaks and decreased genomic stability. It is extremely 
important for cells to maintain genomic integrity during the stages of cell division, a process 
during which thousands of errors are made during genetic duplication; to ensure this integrity, 
the HRR pathway and the non-homologous end-joining pathway (NHEJ), among others, initiate  
Figure 1: Mechanism of radioresistance in certain malignancies.11 
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repair of genetic damage caused by reactive oxygen species (ROS), UV light, and mutagenic 
chemicals.10 
When common repair pathways for double-stranded breaks are defective, cells rely more 
heavily on the PARP pathway. In contrast to HRR’s and NHEJ’s functions in dsDNA breaks, the 
primary function of PARP is to identify single-stranded DNA (ssDNA) breaks and initiate the 
enzymatic response necessary to repair these single-stranded breaks.2 Because cancerous cells 
with defective dsDNA repair pathways can utilize functional PARP to maintain genomic 
integrity, the PARP pathway is an excellent target for chemotherapeutic intervention. PARP1 
may contribute to dsDNA break repair in HR deficient cells by promoting alternative end-joining 
(altEJ), an error-prone repair mechanism that functions when HRR and NHEJ fail to respond to 
damage. Notably, PARP1 is often overexpressed in HRR lacking cells.2 Possibly for this reason, 
PARP inhibitors such as olaparib, veliparib, niraparib, and talazoparib (BMN673) are effective 
therapies in tumor cells lacking effective dsDNA repair mechanisms. In tumors with intact HR 
and NHEJ pathways, the role of PARP inhibition in successful treatment is not entirely 
understood. However, multimodal approaches to cancer treatment, including combining radiation 
therapy with chemical agents, show promise in this area: when BMN673 is combined with high 
doses of radiation, tumors become sensitized to radiation damage.2 
 Radiation therapy induces DNA double-stranded breaks, considered the most lethal form 
of genetic damage, in all cells but especially in malignancies with reduced genomic  
stability or rapid division.11 Resistance to radiotherapy represents an obstacle to effective 
treatment. Exposure to radiation initiates a cellular response that includes activation of 
P13K/AKT, MAPK, STAT, and phospholipase C pathways that together increase the rate of cell 
division and post-radiation survival (Figure 1).11 In tumor cells, this cascade can be 
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hyperactivated and leads to increased proliferation due to upregulated dsDNA break repair 
mechanisms like HRR and NHEJ.11 While other PARP inhibitors exhibit only modest 
radiosensitization in tumor cells when combined with radiation therapy, BMN673 mediates 
strong radiosensitization and exhibits increased efficacy in damaging survival mechanisms in 
cancer by inhibiting PARP, NHEJ, and altEJ.11 It also abrogates HRR and enhances double-
stranded break end resection.2 Compared to other PARP inhibitors, it displayed a short window 
of action (approximately 1 hour) and sensitizes tumors to radiation as effectively as NHEJ and 
HRR knockout models.2 While olaparib generates sufficient radiosensitivity at 3 micromol/L, 
BMN673 is effective at concentrations as low as 10 nmol/L; furthermore, maximal 
radiosensitization is achieved in vitro with 50 nmol/L only one hour before irradiation in hamster 
CHO cells.2 In vitro sarcoma experiments with BMN673 plus irradiation, dsDNA breaks were 
suppressed at relatively low radiation doses, irradiation-induced translocations were increased, 
and at high IR doses NHEJ and altEJ were more inhibited in comparison to other PARP 
inhibitors (Figure 2).11 BMN673 in vitro sarcoma experiments suggest that it is a relatively low 
Figure 2: Action of BMN673 on c-NHEJ, HRR, alt-EJ, and double-stranded break resection.11 
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impact and effective chemotherapy, and translational studies are needed to explore its effects in 
combination with radiation therapy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: “BMN673.”12 
Figure 4: “Summary of BMN673 in vitro activity.”13 
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Methods 
I. Cell culture 
 All cell lines were maintained at 37°C in an atmosphere of 5% CO2 and 95% air. 
Rhabdomyosarcoma cell lines BVM02R and BVM05R and osteosarcoma cell line BVM3O were 
obtained from the oncology research labs of Washington University in St. Louis, Missouri which 
derived these lines from mouse sarcoma cells. All cell lines were grown in Dulbecco’s modified 
version of Eagle’s Minimal Essential Medium (DMEM) supplemented with 10% FBS, 1% 
penicillin-streptomycin, and 1% amino acid solution. Cell lines were passed approximately three 
times per week.  
II. Mice 
Three orders of thirty wild-type young female C57BL/6 mice (n = 90) were obtained 
from the Jackson Laboratory of Bay Harbor, Maine. Mice were pair-housed in climate-controlled 
suites in accordance with institutional guidelines and given access to food and water ad libitum. 
Each group of thirty mice received subcutaneous injection under anesthesia (2% isoflurane, 98% 
O2) of BVM05R, BVM02R, or BVM3O on the right flank behind the hip joint. Approximately 
three million cells were injected into each mouse for each cell line. In each group, mice were 
randomly assigned to one of four treatment cohorts: control, BMN673 alone, radiation therapy 
alone, or BMN673 combined with radiation therapy. All mice received oral gavage with 
BMN673 groups receiving 0.33 mg/kg drug daily prior to radiation therapy or sham radiation. 
Non-drug groups received vehicle via oral gavage. Tumors were measured beginning on the first 
day that tumors could be palpated with an area of approximately 2.5 mm x 2.5 mm. After this 
point, tumors were measured every other day until euthanasia due to tumor burden or at the end 
of 6-8 weeks. Tumor measurement was executed with a digital caliper. Mice were euthanized in 
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a CO2 chamber in accordance with institutional guidelines when removal criteria were met 
concerning ulceration (2.0 x 2.0 mm), tumor size (greater than 1.6 x 1.6 cm), or general health 
concern (excessive anxiety-like symptoms indicated by hunched posture, weight loss, and 
reduced mobility). 
III. Radiation 
 Mice were subjected to sham radiation or radiation at the Ohio State University’s College 
of Medicine Irradiation Core. The Radsource X-Ray Irradiator used is located in the vivarium of 
the Biological Research Tower on the medical campus. Mice in radiation treatment groups were 
subjected to four consecutive days of three gray (gy = J/kg) X-ray radiation and received 
anesthesia (2% isoflurane, 98% O2) prior to radiation. 
IV. Statistical analysis 
 Statistical analysis was conducted using UsableStats two-sample independent t-testing. 
Probability values were calculated between each data point using the final mean tumor volumes 
and final week standard deviations. 
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Results 
I. Observational results for mice injected with BVM02R, BVM05R, and BVM3O 
Mice injected with BVM02R and BVM05R rhabdomyosarcoma cells and BVM3O 
osteosarcoma cells exhibited rapid tumorigenesis and tumor growth over a period of six to eight 
weeks. In the BVM05R group, six mice developed exposed ulcerations on the middle portions of 
their tumor bodies due to necrosis. Mice with tumor ulcerations greater than 2.0 x 2.0 millimeters 
were euthanized via CO2 chamber. Ulcerations typically developed in the center of the top 
portion of the tumor body. Tumors did not metastasize outside of the local area, and tumor size 
did not interfere with walking motion. In all groups, mice did not experience prolonged weight 
loss of greater than 10% and consumed food and water at normal rates. Mice with larger tumors, 
such as those in control groups, did not exhibit immobility or other anxiety-like symptoms. 
These mice responded to handling during tumor measurement similarly to other mice. There 
were no observed differences in behavior or activity between groups. Tumors with dimensions 
below 7.5 cm x 7.5 centimeters were symmetrical, while tumors with dimensions larger than 7.5 
cm x 7.5 cm frequently exhibited elongation along the body’s vertical axis. Larger tumors 
occasionally developed polyp-like growths on or near the base of the larger tumor.   
 
II. Tumor measurements for BVM02R injected mice (Figure 5a, b; Table 1) 
The BVM02R-injected mice tumor measurement results were similar to the other 
rhabdomyosarcoma group (BVM05R). The experimental groups (BMN673, RT, and BMN673 + 
RT) all exhibited significantly inhibited tumor growth in comparison to control mice. The control 
group showed the fastest tumor growth over the course of the study. The BMN673 group that 
received sham radiation showed reduced tumor growth in each week compared to control (final 
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mean tumor volume difference = 244.5 mm3, p = 0.0112). The radiation group that did not 
receive BMN673 exhibited reduced tumor growth in each week compared to BMN673 alone 
(final mean tumor volume difference = 127 mm3, p = 0.0274). The BMN673 plus radiation 
group exhibited the slowest tumor growth and had the lowest mean tumor measurements in every  
week compared to the RT group (final mean tumor volume difference = 119.7 mm3, p = 0.0287). 
These results show that BMN673 significantly sensitizes rhabdomyosarcoma cells to radiation 
therapy in the BVM02R tumor model. 
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Figure 5: BMN673 sensitizes BVM02R (rhabdomyosarcoma) sarcoma tumors to radiation therapy.  From darkest to 
lightest coloring: Control, BMN673 alone, RT alone, BMN673+RT groups. BMN673 administered at 0.33mg/kg daily in 
BMN673-receiving mice. Radiation therapy administered at three gray over four consecutive days.  
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III. Tumor measurements for BVM05R injected mice (Figure 6a, b; Table 1) 
As mentioned above, the BVM05R tumor model experiment yielded similar results to  
that of the other rhabdomyosarcoma cell line, BVM02R. All treatment groups showed 
significantly reduced tumor volume in comparison to control at the end of the study, and 
BMN673 significantly increased sensitization to radiation therapy. The administration of 
BMN673 without radiation resulted in reduced tumor formation compared to the control (final 
mean tumor volume difference = 411.5 mm3, p = 0.0152). This indicates, again, that the use of 
BMN673 as a chemotherapeutic agent in rhabdomyosarcoma is effective even without the 
combination of radiation therapy. The RT group exhibited even more inhibited tumor growth 
compared to control (final mean tumor volume difference = 584.4 mm3, p = 0.0032), reinforcing  
the fact that radiation therapy alone was more effective than BMN673 alone. When these 
treatments were combined, the BMN673+RT group was even more effective than radiation alone 
(final mean tumor volume difference = 215.1 mm3, p = 0.0139). 
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Figure 6: BMN673 sensitizes BVM05R (rhabdomyosarcoma) sarcoma tumors to radiation therapy.  From darkest to 
lightest coloring: Control, BMN673 alone, RT alone, BMN673+RT groups. BMN673 administered at 0.33mg/kg daily in 
BMN673-receiving mice. Radiation therapy administered at three gray over four consecutive days.  
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IV. Tumor measurements for BVM3O injected mice (Figure 7a, b; Table 1) 
BMN673 did not sensitize the BVM3O osteosarcoma tumor to radiation therapy. While 
all treatment groups were significantly more effective at reducing final tumor volume than 
control, the BMN673+RT group tumor measurements were almost exactly the same as those of 
the BMN673 group (final mean tumor volume difference = 1.7 mm3, p = 0.4949). The least 
effective treatment was radiation therapy alone; however, radiation therapy still caused 
significant inhibition of tumor growth compared to control (final mean tumor volume difference 
= 264.5 mm3, p = 0.0162). These results indicate that the most effective treatment in treating 
osteosarcoma was BMN673; the combination of this drug with radiation did not result in reduced 
tumor progression, and radiation therapy alone was less effective than BMN73 alone.  
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Figure 7: BMN673 does not sensitize BVM3O (rhabdomyosarcoma) sarcoma tumors to radiation therapy.  From darkest 
to lightest coloring: Control, BMN673 alone, RT alone, BMN673+RT groups. BMN673 administered at 0.33mg/kg daily 
in BMN673-receiving mice. Radiation therapy administered at three gray over four consecutive days.  
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BVM02R Control BMN673 RT BMN673 + RT 
Control   p = 0.0112 p = 0.0011  p = 0.0002 
BMN673 244.5   p = 0.0274  p = 0.0007 
RT 371.5 127   p = 0.0287 
BMN673+RT 491.2 246.7 119.7   
     
BVM05R Control BMN673 RT BMN673 + RT 
Control   p = 0.0152 p = 0.0032 p = 0.0005 
BMN673 411.5   p = 0.0478 p = 0.0002 
RT 584.4 172.9   p = 0.0139 
BMN673+RT 799.6 388.1 215.1   
       
BVM3O Control BMN673 RT BMN673 + RT 
Control   p = 0.0032 p = 0.0162 p = 0.0012  
BMN673 471.0   p = 0.0560  p = 0.4949 
RT 264.5 206.5   p = 0.0236 
BMN673+RT 472.7 1.7 208.2   
Table 1: Final mean tumor volume differences and p values for Control, BMN673, RT, and 
BMN673+RT in BVM02R, BVM05R, and BVM3O. Final mean tumor volume differences (blue) 
correspond to groups listed on top and on the left. Statistical analysis conducted using two-sample 
independent t-test. Probability values (orange) correspond to row and column groups. 
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Discussion 
 The purpose of our study was to investigate the promising results of in vitro experiments 
of BMN673 in an animal model. Our investigation of BMN673’s potential to sensitize sarcoma 
to irradiation in vivo confirmed the conclusions drawn from in vitro studies conducted by the lab 
of Dr. George Iliakis. The drug proved to be an effective intervention when used alone in models 
of rhabdomyosarcoma and osteosarcoma, and it proved to be even more effective as a 
combinational therapy when combined with x-ray radiation in rhabdomyosarcoma; however, this 
was not an effective combination in osteosarcoma treatment. The results we generated 
necessitate further exploration of the mechanisms underlying sensitization and resistance to 
radiation therapy. 
 We selected rhabdomyosarcoma as the primary focus of the study because it is one of the 
most common soft tissue sarcomas and responds to both chemotherapy and radiotherapy in 
humans. We selected osteosarcoma because it is susceptible to chemotherapy, but it is not very 
susceptible to radiotherapy; in fact, osteosarcoma is almost always treated with surgery and 
chemotherapy because it is notoriously resistant to RT.14 This resistance is likely mediated by 
microRNA-driven upregulation of enzymes like human apurinic/apyrimidinic endonuclease 1 
(APE1).15 In light of our results, this response profile in comparison with that of 
rhabdomyosarcoma provides evidence that the observed effectiveness of the combined 
BMN673+RT treatment group was caused by a novel, synergistic mechanism rather than the 
additive effects of distinct mechanisms. Our results indicate that (1) the growth-inhibiting 
mechanism of BMN673 is not the same as that of radiotherapy, though the two may overlap, (2) 
that BMN673 has moderate activity as a singular therapy in both models, (3) that BMN673 
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increases the susceptibility of rhabdomyosarcoma to radiation therapy, and (4) that BMN673 
does not potentiate radiation in osteosarcoma, a subtype of sarcoma that is resistant to radiation.  
 The mechanism of this synergistic effect remains unknown. We know that radiation 
causes the formation of double- and single-stranded breaks in DNA, and that BMN673 inhibits 
the action of PARP1. However, PARP1 primarily functions in the repair of single-stranded 
breaks; in rhabdomyosarcoma, the double-stranded repair mechanisms are likely intact. HHR 
and NHEJ may even be upregulated in response to irradiation. A possible explanation of the 
observed effect is that PARP1 is unable to repair single-stranded breaks caused by radiation, and 
when single-stranded breaks in DNA reach a replication fork, double-stranded breaks often form. 
The tumor cells’ error-free repair pathways may be overwhelmed by genomic instability, and the 
cells may begin to partially rely on altEJ and other error-prone repair mechanisms to overcome 
this instability. However, in addition to PARP1 inhibition, BMN673 was shown in vitro to 
reduce the activity of secondary repair pathways like altEJ and primary pathways like HRR and 
NHEJ and, in addition, to enhance end resection of double stranded breaks. In vitro, the 
cumulative effect of these actions resulted in tumor responses to PARP inhibition seen only in 
HRR and NHEJ knockout models. It is likely that BMN673 exerted a similar battery of 
molecular mechanisms in the animals; however, this remains unknown. If BMN673 is inhibiting 
PARP, modulating HRR and NHEJ, reducing the activity of altEJ, and interfering with the 
resection of double-stranded breaks, it is a significant and promising intervention for sarcoma 
and for many other cancers as a singular therapy. Even more so, the combination of BMN673 
with irradiation proved to be significantly more effective than either therapy alone, and further 
translational studies are needed to develop a better idea of the molecular mechanics and safety 
profile of this drug in combination with RT.  
  Jacob 
 
 19 
Works Cited 
1. Cao, J., An, Q., Wang, L. "Pediatric sarcomas (Review)". Oncology Letters 15.2 (2018): 
1397-1402. 
2. Soni, A. et.al. “Inhibition of Parp1 by BMN673 Effectively Sensitizes Cells to 
Radiotherapy by Upsetting the Balance of Repair Pathways Processing DNA Double-
Strand Breaks.” Institute of Medical Radiation Biology, University of Duisburg-Essen 
Medical School. Molecular Cancer Therapeutics. 3 July 2018.  
3. Morales, Julio et al. “Review of poly (ADP-ribose) polymerase (PARP) mechanisms of 
action and rationale for targeting in cancer and other diseases.” Critical reviews in 
eukaryotic gene expression vol. 24,1 (2014): 15-28.  
4. Yamasaki et.al. “Synovial sarcoma cell lines showed reduced DNA repair activity and 
sensitivity to a PARP inhibitor.” Department of Innovative Seeds Evaluation, National 
Cancer Center Research Institute. 2016. Genes to Cells 21, 852-860.  
5. Hoang, Ngoc T et al. “A review of soft-tissue sarcomas: translation of biological 
advances into treatment measures.” Cancer management and research vol. 10 1089-
1114. 10 May, 2018. 
6. Gibbs, P. et.al. “Stem-Like Cells in Bone Sarcomas: Implications for Tumorigenesis.” 
Neoplasia 7, 11. November. 
7. Randall, R., et al. “Bone Sarcomas.” Cancer Network. 2 Nov. 2015,  
8. Pisters, Peter W. T., et al. “Soft-Tissue Sarcomas.” Cancer Network. 2 June 2016,  
9. Singhi, Eric K et al. “Metastatic Soft Tissue Sarcomas: A Review of Treatment and New 
Pharmacotherapies.” P & T: A Peer-Reviewed Journal for Formulary Management vol. 
43,7 (2018): 410-429. 
10. Brandsma, Inger, and D.C. Gent. “Pathway choice in DNA double strand break repair: 
observations of a balancing act.” Genome integrity vol. 3,1 9. 27 Nov. 2012, 
doi:10.1186/2041-9414-3-9 
11. Toulany, Mahmoud. “Targeting DNA Double-Strand Break Repair Pathways to Improve 
Radiotherapy Response.” Genes vol. 10,1 25. 4 Jan. 2019, doi:10.3390/genes10010025 
12. “Talazoparib (BMN673).” Selleck Chemistry. PARP Inhibitors. April, 2020. 
  Jacob 
 
 20 
13. Shen, Y., et.al. “BMN673, a Novel and Highly Potent PARP1/2 Inhibitor for the 
Treatment of Human Cancers and DNA Repair Deficiency.” Clinical Cancer Research, 
19(18):5003-15. September 15, 2013. 
14. Schwarz, R. et.al. “The role of radiotherapy in osteosarcoma.” Cancer Treat Res. 2019. 
15. Beaury, M., Kelly-Beaury, M., Sharp, G., Cottrell, J. “A Review of Osteosarcoma 
Therapies.” Journal of Cancer Treatment and Diagnosis. April 24, 2018. 
